The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
Jörg B Schulz; Michael Rainer; Hans-Hermann Klünemann; Alexander Kurz; Stefanie Wolf; Kati Sternberg; Frank Tennigkeit (Profiled Author: Kurz, Alexander)
Department of Neurology, University Medical Center, RWTH Aachen, Aachen, Germany. firstname.lastname@example.org
Journal of Alzheimer's disease : JAD 2011;25(3):463-75.
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued for 8 weeks, followed by a 4-week wash-out period. The primary efficacy endpoint was the change from baseline in the Consortium to Establish a Registry for Alzheimer's Disease -Neuropsychological Battery (CERAD-NP) total score. Secondary efficacy endpoints included change from baseline in Functional Communication Language Inventory (FLCI) and ADCS-ADL19 total score, and the response from baseline in Clinical Global Impression of Change (CGI-C). The CERAD-NP total score improved significantly after 12 weeks of once-daily memantine treatment compared with baseline (5.9 ± 8.8; p < 0.0001). The FLCI total score improved significantly after 12 weeks compared with baseline (4.4 ± 6.8; p < 0.0001). These significant improvements were already observed after 4 and 8 weeks of once-daily memantine treatment and persisted after a 4-week wash-out period. ADCS-ADL19 total scores showed only slight increases from baseline, and CGI-C indicated that the majority of patients experienced an improvement or stabilization of the disease after 12 weeks. At least one Treatment-Emergent Adverse Event was reported by 38 (39.2%) patients. In patients with moderate to severe AD, once-daily memantine (20 mg) treatment significantly improved cognition and functional communication and was found to have a favorable safety and tolerability profile.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Dekosky, Steven T
30 September 1999 - 31 July 2010
NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE
Total Funding: $ 30,761,491
Knopman, David S
30 September 2003 - 31 August 2007
NATIONAL INSTITUTE ON AGING
Total Funding: $ 1,649,076
MORRIS, JOHN C
5 February 1996 - 31 December 2001
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Total Funding: $ 1,529,999
Janine Diehl-Schmid; Hans Förstl; Robert Perneczky; Corina Pohl; Alexander KurzInternational journal of geriatric psychiatry 2008;23(7):754-9.
Ralf Ihl; Steven Ferris; Philippe Robert; Bengt Winblad; Serge Gauthier; Frank TennigkeitInternational journal of geriatric psychiatry 2012;27(1):15-21.
H Förstl; S S Stamouli; W Janetzky; A Galanopoulos; C Karageorgiou; M TzanakakiDementia and geriatric cognitive disorders 2011;32(4):267-72.
Appears in this Publication
Author of this Publication